

Quick Reference Guide

Guidelines

Coronary artery disease (CAD) in general population

- World Health Organization Prevention of Cardiovascular Disease: Pocket guidelines for assessment and management of cardiovascular risk; [Part 2: Management of people with established coronary heart disease, cerebrovascular disease or peripheral vascular disease \(secondary prevention\)](#).^{*} Accessed 18 April 2011.
- [European Society of Cardiology Full Guidelines and Pocket Guidelines on the Management of Stable Angina Pectoris \(2006\)](#).^{*} Accessed 18 April 2011.
- [European Society of Cardiology Full Guidelines and Pocket Guidelines on Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation \(2007\)](#).^{*} Accessed 3 May 2011.
- [European Society of Cardiology Full Guidelines and Pocket Guidelines on Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation \(2008\)](#).^{*} Accessed 3 May 2011.
- Patrono C, Baigent C, Hirsh J, Roth G; American College of Chest Physicians. [Antiplatelet Drugs American College of Chest Physicians Evidence-Based Clinical Practice Guidelines \(8th Edition\)](#).^{*} *Chest*. 2008;133:199S–233S.

For information on cardiovascular disease prevention please refer to the main cardiovascular disease department page of this website, where a downloadable document on prevention is available.

Key Publications

Reviews

1. Baker JV, Lundgren JD. [Cardiovascular implications from untreated human immunodeficiency virus infection](#).^{*} *Eur Heart J*. 2011;32:945–951.
2. Grinspoon SK, Grunfeld C, Kotler DP, et al. [State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary](#).^{*} *Circulation*. 2008;118:198–210.
3. Ho JE, Hsue PY. [Cardiovascular manifestations of HIV infection](#).^{*} *Heart*. 2009;95:1193–1202.
4. Passalaris JD, Sepkowitz KA, Glesby MJ. [Coronary artery disease and human immunodeficiency virus infection](#).^{*} *Clin Infect Dis*. 2000;31:787–797.
5. Boccara F, Cohen A. [Coronary artery disease and stroke in HIV-infected patients: prevention and pharmacological therapy](#).^{*} *Adv Cardiol*. 2003;40:163–184.

6. Malvestutto CD, Aberg JA. [Coronary heart disease in people infected with HIV](#).* *Cleve Clin J Med*. 2010;77(8):547–556.
7. Khunnawat C, Mukerji S, Havlichek D Jr, Touma R, Abela GS. [Cardiovascular manifestations in human immunodeficiency virus-infected patients](#).* *Am J Cardiol*. 2008;102:635–642.

Acute coronary syndromes in HIV-infected patients

1. Boccara F, Mary-Krause M, Teiger E, et al. [Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis](#).* *Eur Heart J*. 2011;32:41–50.
2. Hsue PY, Giri K, Erickson S, et al. [Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection](#).* *Circulation*. 2004;109:316–319.
3. Ambrose JA, Gould RB, Kurian DC, et al. [Frequency of and outcome of acute coronary syndromes in patients with human immunodeficiency virus infection](#).* *Am J Cardiol*. 2003;92:301–303.
4. Matetzky S, Domingo M, Kar S, et al. [Acute myocardial infarction in human immunodeficiency virus-infected patients](#).* *Arch Intern Med*. 2003;163:457–460.

Prediction of CAD

1. Kaplan RC, Kingsley LA, Sharrett AR, et al. [Ten-year predicted coronary heart disease risk in HIV-infected men and women](#).* *Clin Infect Dis*. 2007;45(8):1074–1081.
2. Friis-Møller N, Thiébaud R, Reiss P, et al. [Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study](#).* *Eur J Cardiovasc Prev Rehabil*. 2010;17:491–501.
3. Moreira Guimarães MM, Bartolomeu Greco D, Ingles Garces AH, et al. [Coronary heart disease risk assessment in HIV-infected patients: a comparison of Framingham, PROCAM and SCORE risk assessment functions](#).* *Int J Clin Pract*. 2010;64:739–745.
4. Bucher HC, Rickenbach M, Young J, et al. [Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy](#).* *Antivir Ther*. 2010;15:31–40.
5. Rossi R, Nuzzo A, Guaraldi G, et al. [The role of the Framingham risk score to predict the presence of subclinical coronary atherosclerosis in patients with HIV infection](#).* *J Acquir Immune Defic Syndr*. 2009;52:303–304.
6. Hsue PY, Squires K, Bolger AF, et al. [Screening and assessment of coronary heart disease in HIV-infected patients](#).* *Circulation*. 2008;118:e41–47.
7. Schambelan M, Wilson PW, Yarasheski KE, et al. [Development of appropriate coronary heart disease risk prediction models in HIV-infected patients](#).* *Circulation*. 2008;118:e48-53.

Atherosclerosis surrogate markers

1. Grunfeld C, Delaney JA, Wanke C, et al. [Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study.](#)* *AIDS*. 2009;23:1841–1849.
2. Hulten E, Mitchell J, Scally J, Gibbs B, Villines TC. [HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies.](#)* *Heart*. 2009;95:1826–1835.
3. Fitch KV, Lo J, Abbara S, et al. [Increased coronary artery calcium score and noncalcified plaque among HIV-infected men: relationship to metabolic syndrome and cardiac risk parameters.](#)* *J Acquir Immune Defic Syndr*. 2010;55:495–499.
4. Lo J, Abbara S, Shturman L, et al. [Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men.](#)* *AIDS* 2010;24:243–253.
5. Guaraldi G, Stentarelli C, Zona S, et al. [Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects.](#)* *Atherosclerosis* 2010;208:222–227.
6. Medina S, Wessman D, Krause D, Stepenosky J, Boswell G, Crum-Cianflone N. [Coronary aging in HIV-infected patients.](#)* *Clin Infect Dis*. 2010;51:990–993.
7. Guaraldi G, Zona S, Alexopoulos N, et al. [Coronary aging in HIV-infected patients.](#)* *Clin Infect Dis*. 2009;49:1756–1762.

Risk factors for myocardial infarction

1. Triant VA, Lee H, Hadigan C, Grinspoon SK. [Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease.](#)* *J Clin Endocrinol Metab*. 2007;92:2506–2512.
2. Boccara F. [Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors.](#)* *AIDS*. 2008;22(Suppl 3):S19–26.
3. Friis-Møller N, Weber R, Reiss P, et al; DAD study group. [Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study.](#)* *AIDS*. 2003;17:1179–1193.